CTI BioPharma Corp.

Keros Therapeutics' Elritercept Shows Promise in Myelodysplastic Syndromes and Myelofibrosis Trials

7 months ago

• Keros Therapeutics is set to release updated Phase II trial data for Elritercept in Q4 2024, targeting ineffective hematopoiesis in myelodysplastic syndromes (MDS) and myelofibrosis (MF). • Elritercept has demonstrated durable transfusion independence and improved patient-reported fatigue in lower-risk MDS, potentially addressing anemia. • In myelofibrosis trials, Elritercept, alone or with Jakafi, has shown improvements in hematopoiesis, spleen volume reduction, and enhanced total symptom scores. • Keros Therapeutics is also advancing Cibotercept for pulmonary arterial hypertension and KER-065 for obesity and neuromuscular disorders.